DelveInsight’s ‘Heart Failure Pipeline Insight 2023‘ report provides comprehensive global coverage of pipeline Heart Failure therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Heart Failure pipeline domain.
For Heart Failure emerging drugs, the Heart Failure pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key Takeaways from the Heart Failure Pipeline Report
- DelveInsight’s Heart Failure Pipeline analysis depicts a robust space with 75+ active players working to develop 90+ pipeline therapies for Heart Failure treatment.
- The leading Heart Failure companies include Windtree Therapeutics, TreeFrog Therapeutics, Torrent Pharmaceuticals, Tenaya Therapeutics, Tasly Pharmaceuticals, Sulfagenix, Stealth BioTherapeutics, SQ Innovation, Shanghai Hongyitang Biopharmaceutical Technology, scPharmaceuticals, Sardocor, Sana Biotechnology, Salubris Biotherapeutics, Roche, Rivus Pharmaceuticals, Ribomic, Renova Therapeutics, Relaxera, Regeneron Pharmaceuticals, Recardio, Quantum Genomics, Procella Therapeutics, Precigen, Pfizer, Paradigm biopharmaceuticals, Palatin Technologies, Orizuru Therapeutics, Olatec Therapeutics, Novo Nordisk, Metcela, Mesoblast Inc., Merck & Co, Lexicon Pharmaceuticals, Janssen Research & Development, Ionis Pharmaceuticals, InvivoSciences, Intra-Cellular Therapies, Innolife, Imbria Pharmaceuticals, Imara Inc, Hyloris Pharmaceuticals, Help Therapeutics, Heartseed, HAYA Therapeutics, GlaxoSmithKline, GB Sciences, Fujifilm Corporation, Evotec SE, Eli Lilly and Company, Edgewise Therapeutics, DiNAQOR, Cytokinetics, CUORiPS, Chong Kun Dang, Cardurion Pharmaceuticals, Cardiora, Cardior Pharmaceuticals, Cardiol Therapeutics, CardioCell, Bristol Myers Squibb, Boryung Pharmaceutical, BlueRock Therapeutics, BioCardia, Berlin Cures, BenevolentAI, Bayer, Athersys, AstraZeneca, Asklepios Biopharmaceutical, Antlia Biosciences, AnaCardio, AliveGen, Actelion Pharmaceuticals, and others are evaluating their lead assets to improve the Heart Failure treatment landscape.
- Key Heart Failure pipeline therapies in various stages of development include Istaroxime, SERCA2a activators, hiPSC-derived cardiac cells, TRC 041266, TN-301, AAV-Based Research Project, DWORF, Qishenyiqi Dripping Pills, SG1002, Elamipretide, SQIN-01, TSG-01, Furoscix, SRD-001, SC 187, JK-07, Pirfenidone, HU6, RBM-003, RT 100, Relaxin-2, REGN5381, REC 02, Firibastat, Heart Failure Research Project, PROC-001, INXN-4001, Sildenafil citrate, APD-418, Prazosin hydrochloride, Pentosan Polysulfate Sodium (PPS), PL 3994, IPSC-derived cardiomyocyte, Dapansutrile, Semaglutide, MTC001, Rexlemestrocel-L (Revascor), Ertugliflozin, Sotagliflozin, Rivaroxaban, IONIS-AGT-LRx, IVS201, Lenrispodun, INL 1, IMB-101, IMR-687, Milrinone, Metolazone IV, HiCM-188, HS-001, Antisense oligonucleotide based therapy, GSK3884464, Research programme: heart failure therapeutics, iPSC-derived cardiac progenitor cells, IPSC-Based Tissue Therapy, Tirzepatide, LY3461767, EDG 002, DINA-007/A, DINA-007/B, Omecamtiv mecarbil, CK-136, IPSC-derived cell, CKD-349, CRD 733, Research programme: cardiovascular therapies, CRD-102, CDR132L, CardiolRx, Allogeneic Mesenchymal Bone Marrow Cells, Mavacamten, BMS-986231, FA relaxin, ROMK inhibitor, BR1016C, BR1016A, Research programme: induced pluripotent stem cell therapeutics, CardiAMP cell therapy, CardiALLO Cell Therapy, BC-007, Research programme: therapeutics, Finerenone (BAY 94-8862), Pecavaptan, MultiStem cell therapy, AZD4831, AZD 9977, AZD-8601, and others.
- In June 2023, Daiichi Sankyo, Inc. and American Regent, Inc., a Daiichi Sankyo Group company, announced that the US Food and Drug Administration (FDA) has approved INJECTAFER (ferric carboxymaltose injection) for the treatment of iron deficiency in adult patients with New York Heart Association class II/III heart failure to improve exercise capacity.
- In May 2023, Lexicon Pharmaceuticals, Inc. announced that the US Food and Drug Administration (FDA) has approved INPEFA (sotagliflozin), a once-daily oral tablet, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors.
- In March 2023, Cardiol Therapeutics announced study results from one of its international collaborating research centers demonstrating that its pharmaceutically manufactured cannabidiol significantly prevents cardiac dysfunction and the development of fibrosis and cardiomyocyte hypertrophy in a pre-clinical model of heart failure and reduces expression of key inflammatory and fibrotic markers.
- In March 2023, Sequana Medical announced positive results from its Phase 1 single-center, single-arm, single-dose trial (CHIHUAHUA) with its second-generation DSR product (DSR 2.0).
Request a sample and discover the recent breakthroughs happening in the Heart Failure pipeline landscape @ Heart Failure Pipeline Outlook
Heart Failure Overview
Heart failure is a syndrome caused by anatomical and functional myocardial abnormalities that limit ventricular filling or blood ejection. The most common cause of heart failure is decreased left ventricular myocardial function. Major pathogenic mechanisms leading to heart failure include increased hemodynamic overload, ischemia-related dysfunction, ventricular remodeling, excessive neuro-humoral stimulation, abnormal myocyte calcium cycling, excessive or inadequate extracellular matrix proliferation, accelerated apoptosis, and genetic mutations. Heart failure reduces a patient’s functional capacity and raises the chance of death. Effective disease diagnosis and treatment are crucial for avoiding recurring hospitalizations, improving quality of life, and improving patient outcomes.
A multimodal approach to heart failure treatment is required, including patient education, an effective medication regimen to promote cardiac contractility, and the prevention/limitation of exacerbations. The chief symptoms of heart failure are dyspnea and fatigue, which can restrict exercise tolerance and result in pulmonary and splanchnic congestion as well as peripheral edema. Heart failure remains a challenging disease, and it is today regarded as the most difficult task in cardiovascular medicine and surgery.
Find out more about Heart Failure medication @ New Drug for Heart Failure
Heart Failure Treatment Analysis: Drug Profile
Tirzepatide: Eli Lilly and Company
Tirzepatide is a once-weekly dual GIP/GLP-1 receptor agonist that combines the activities of both incretins into a single molecule. GIP is a hormone that may supplement GLP-1’s actions. GIP has been found in preclinical animals to reduce food intake and increase energy expenditure, resulting in weight loss, and when paired with a GLP-1 receptor agonist, may have larger effects on glucose and body weight. Tirzepatide is currently in phase 3 development for the treatment of chronic obesity and heart failure with preserved ejection fraction (HFpEF).
Finerenone (BAY94-8862): Bayer
Finerenone (BAY 94-8862) is a novel, non-steroidal, selective mineralocorticoid receptor antagonist (MRA) that has been demonstrated to inhibit the detrimental consequences of an overactive mineralocorticoid receptor (MR) system. Overactivation of the MR is a primary cause of heart and kidney injury. Current steroidal MRAs on the market have been shown to lower cardiovascular mortality in individuals with heart failure with reduced ejection fraction (HFrEF). However, because of the risk of hyperkalemia, renal impairment, and anti-androgenic/progestogenic side effects, they are frequently underutilized.
Key Heart Failure Therapies and Companies
- Tirzepatide: Eli Lilly and Company
- Finerenone (BAY94-8862): Bayer
- Firibastat: Quantum Genomics
- HU 6: Rivus Pharmaceuticals
- Elamipretide: Stealth BioTherapeutics
- TN-301: Tenaya Therapeutics
Learn more about the novel and emerging Heart Failure pipeline therapies @ Heart Failure Clinical Trials
Heart Failure Therapeutics Assessment
- By Product Type
- Monotherapy
- Combination Therapy
- By Stage
- Discovery
- Pre-Clinical
- Phase I
- Phase II
- Phase III
- Pre-registration
- By Route of Administration
-
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
- By Molecule Type
- Oligonucleotide
- Peptide
- Small molecule
Scope of the Heart Failure Pipeline Report
-
- Coverage: Global
- Key Heart Failure Companies: Zensun (Shanghai) Sci & Tech, Windtree Therapeutics, TreeFrog Therapeutics, Torrent Pharmaceuticals, Tenaya Therapeutics, Tasly Pharmaceuticals, Sulfagenix, Stealth BioTherapeutics, SQ Innovation, Shanghai Hongyitang Biopharmaceutical Technology, scPharmaceuticals, Sardocor, Sana Biotechnology, Salubris Biotherapeutics, Roche, Rivus Pharmaceuticals, Ribomic, Renova Therapeutics, Relaxera, Regeneron Pharmaceuticals, Recardio, Quantum Genomics, Procella Therapeutics, Precigen, Pfizer, Paradigm biopharmaceuticals, Palatin Technologies, Orizuru Therapeutics, Olatec Therapeutics, Novo Nordisk, Metcela, Mesoblast Inc., Merck & Co, Lexicon Pharmaceuticals, Janssen Research & Development, Ionis Pharmaceuticals, InvivoSciences, Intra-Cellular Therapies, Innolife, Imbria Pharmaceuticals, Imara Inc, Hyloris Pharmaceuticals, Help Therapeutics, Heartseed, HAYA Therapeutics, GlaxoSmithKline, GB Sciences, Fujifilm Corporation, Evotec SE, Eli Lilly and Company, Edgewise Therapeutics, DiNAQOR, Cytokinetics, CUORiPS, Chong Kun Dang, Cardurion Pharmaceuticals, Cardiora, Cardior Pharmaceuticals, Cardiol Therapeutics, CardioCell, Bristol Myers Squibb, Boryung Pharmaceutical, BlueRock Therapeutics, BioCardia, Berlin Cures, BenevolentAI, Bayer, Athersys, AstraZeneca, Asklepios Biopharmaceutical, Antlia Biosciences, AnaCardio, AliveGen, Actelion Pharmaceuticals, and others.
- Key Heart Failure Pipeline Therapies: Recombinant Human Neuregulin-1β (rhNRG-1), Istaroxime, SERCA2a activators, hiPSC-derived cardiac cells, TRC 041266, TN-301, AAV-Based Research Project, DWORF, Qishenyiqi Dripping Pills, SG1002, Elamipretide, SQIN-01, TSG-01, Furoscix, SRD-001, SC 187, JK-07, Pirfenidone, HU6, RBM-003, RT 100, Relaxin-2, REGN5381, REC 02, Firibastat, Heart Failure Research Project, PROC-001, INXN-4001, Sildenafil citrate, APD-418, Prazosin hydrochloride, Pentosan Polysulfate Sodium (PPS), PL 3994, IPSC-derived cardiomyocyte, Dapansutrile, Semaglutide, MTC001, Rexlemestrocel-L (Revascor), Ertugliflozin, Sotagliflozin, Rivaroxaban, IONIS-AGT-LRx, IVS201, Lenrispodun, INL 1, IMB-101, IMR-687, Milrinone, Metolazone IV, HiCM-188, HS-001, Antisense oligonucleotide based therapy, GSK3884464, Research programme: heart failure therapeutics, iPSC-derived cardiac progenitor cells, IPSC-Based Tissue Therapy, Tirzepatide, LY3461767, EDG 002, DINA-007/A, DINA-007/B, Omecamtiv mecarbil, CK-136, IPSC-derived cell, CKD-349, CRD 733, Research programme: cardiovascular therapies, CRD-102, CDR132L, CardiolRx, Allogeneic Mesenchymal Bone Marrow Cells, Mavacamten, BMS-986231, FA relaxin, ROMK inhibitor, BR1016C, BR1016A, Research programme: induced pluripotent stem cell therapeutics, CardiAMP cell therapy, CardiALLO Cell Therapy, BC-007, Research programme: therapeutics, Finerenone (BAY 94-8862), Pecavaptan, MultiStem cell therapy, AZD4831, AZD 9977, AZD-8601, and others.
Dive deep into rich insights for drugs used for Heart Failure treatment; visit @ Heart Failure Drugs
Table of Contents
| 1. | Introduction |
| 2. | Executive Summary |
| 3. | Heart Failure Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | Heart Failure Pipeline Therapeutics |
| 6. | Heart Failure Pipeline: Late Stage Products (Phase III) |
| 7. | Heart Failure Pipeline: Late Stage Products (Phase III) |
| 8. | Heart Failure Pipeline: Mid-Stage Products (Phase II) |
| 9. | Heart Failure Pipeline: Early Stage Products (Phase I) |
| 10. | Therapeutic Assessment |
| 11. | Inactive Products |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Companies |
| 14. | Key Products |
| 15. | Unmet Needs |
| 16. | Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
For further information on the Heart Failure therapy in the pipeline, reach out @ Heart Failure Medication
Related Reports
Heart Failure Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key heart failure companies, including Help Therapeutics, Heartseed, HAYA Therapeutics, GlaxoSmithKline, GB Sciences, Fujifilm Corporation, Evotec SE, Eli Lilly and Company, Edgewise Therapeutics, among others.
Heart Failure Epidemiology Forecast
Heart Failure Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and heart failure epidemiology trends.
Advanced Heart Failure Pipeline
Advanced Heart Failure Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key advanced heart failure companies, including Sana Biotechnology, Salubris Biotherapeutics, Roche, Rivus Pharmaceuticals, Ribomic, Renova Therapeutics, Relaxera, among others.
Chronic Heart Failure Pipeline
Chronic Heart Failure Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key chronic heart failure companies, including Zensun (Shanghai) Sci & Tech, Cytokinetics, Mesoblast, Shanghai Hongyitang Biopharmaceutical Technology, Tasly Pharmaceuticals, among others.
Acute Heart Failure Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key acute heart failure companies, including Windtree Therapeutics, Adrenomed, Arena Pharmaceuticals, Bristol-Myers Squibb, among others.
Other Trending Reports
Image Guided Surgery Devices Market | Alopecia Market | Chronic Myelogenous Leukemia Market | Neuroblastoma Market | Alzheimer Disease Market | Osteoarthritis Market | Apheresis Market | Scleroderma Market | Hyperhidrosis Market | Opioid Induced Constipation Market | Cervical Intraepithelial Neoplasia Market | Automated External Defibrillators Market | Choroidal Neovascularization Market | Familial Primary Pulmonary Hypertension Market | Meningioma Market | Progressive Multifocal Leukoencephalopathy Market
Related Healthcare Services
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect With Us at LinkedIn | Facebook | Twitter
Contact Us
Sandeep Joshi
info@delveinsight.com
+1(919)321-6187